SDZ NKT 343

Key Product Details

Product Description

SDZ NKT 343 is a highly selective human tachykinin NK₁ receptor antagonist (IC₅₀ values are 0.62 and 451 nM for human and rat receptors respectively) that displays > 130-fold selectivity over human NK₂ and NK₃ receptors. Potently antagonizes SP-induced Ca²⁺ efflux in vitro and inhibits mechanical hyperalgesia in vivo.

Product Specifications for SDZ NKT 343

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Solubility

Preparing Stock Solutions for SDZ NKT 343

The following data is based on the product molecular weight 579.65.

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.73 mL	8.63 mL	17.25 mL
5 mM	0.35 mL	1.73 mL	3.45 mL
10 mM	0.17 mL	0.86 mL	1.73 mL
50 mM	0.03 mL	0.17 mL	0.35 mL

Calculators

Background References

References are publications that support the biological activity of the product.

• Walpole 2-Nitrophenylcarbamoyl-(S)-prolyl-(S)-3-(2-naphthyl)alanyl-N-benzyl-N-methylamide (SDZ NKT 343), a potent human NK1 tachykinin receptor antagonist with good oral analgesic activity in chronic pain models. J.Med.Chem. 1998 PMID: 9703462
• Campbell Selective neurokinin-1 receptor antagonists are anti-hyperalgesic in a model of neuropathic pain in the guinea-pig. Neuroscience. 1998 PMID: 9758219
• Walpole Comparative, general pharmacology of SDZ NKT 343, a novel, selective NK1 receptor antagonist. Br.J.Pharmacol. 1998 PMID: 9630347

Product Documents for SDZ NKT 343